Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

AI Briefing

• – Viatris to Outline its Vision for Sustained Revenue and Earnings Growth
• – Evolving into more durable portfolio of higher-margin generics, value-added medicines and established brands
• – Expecting impactful near-term launches of fast-acting Meloxicam and Low-Dose Estrogen Weekly Patch